Abstract:Cancer stem cells (CSCs) found within cancer tissue play a pivotal role in its resistance to therapy and its potential to metastasize, contributing to elevated mortality rates among patients. Significant strides in understanding the molecular foundations of CSCs have led to preclinical investigations and clinical trials focused on CSC regulator β-catenin signaling targeted interventions in malignancies. As part of the ongoing advancements in marine-organism-derived compound development, it was observed that among the six analogs of Renieramycin T (RT), a potential lead alkaloid from the blue sponge Xestospongia sp., the compound DH_32, displayed the most robust anti-cancer activity in lung cancer A549, H23, and H292 cells. In various lung cancer cell lines, DH_32 exhibited the highest efficacy, with IC50 values of 4.06 ± 0.24 μM, 2.07 ± 0.11 μM, and 1.46 ± 0.06 μM in A549, H23, and H292 cells, respectively. In contrast, parental RT compounds had IC50 values of 5.76 ± 0.23 μM, 2.93 ± 0.07 μM, and 1.52 ± 0.05 μM in the same order. Furthermore, at a dosage of 25 nM, DH_32 showed a stronger ability to inhibit colony formation compared to the lead compound, RT. DH_32 was capable of inducing apoptosis in lung cancer cells, as demonstrated by increased PARP cleavage and reduced levels of the proapoptotic protein Bcl2. Our discovery confirms that DH_32 treatment of lung cancer cells led to a reduced level of CD133, which is associated with the suppression of stem-cell-related transcription factors like OCT4. Moreover, DH_32 significantly suppressed the ability of tumor spheroids to form compared to the original RT compound. Additionally, DH_32 inhibited CSCs by promoting the degradation of β-catenin through ubiquitin–proteasomal pathways. In computational molecular docking, a high-affinity interaction was observed between DH_32 (grid score = −35.559 kcal/mol) and β-catenin, indicating a stronger binding interaction compared to the reference compound R9Q (grid score = −29.044 kcal/mol). In summary, DH_32, a newly developed derivative of the right-half analog of RT, effectively inhibited the initiation of lung cancer spheroids and the self-renewal of lung cancer cells through the upstream process of β-catenin ubiquitin–proteasomal degradation.

Novel Mechanism of Ethaselen in Poorly Differentiated Colorectal RKO Cell Growth Inhibition: Simultaneous Regulation of TrxR Transcription, Expression and Enzyme Activity.

Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.

Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells Via Β-Catenin Proteasomal Degradation in Human Lung Cancer

Dose-biomarker-response Modeling of the Anticancer Effect of Ethaselen in a Human Non-Small Cell Lung Cancer Xenograft Mouse Model

Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo

Ethaselen: a Novel Organoselenium Anticancer Agent Targeting Thioredoxin Reductase 1 Reverses Cisplatin Resistance in Drug-Resistant K562 Cells by Inducing Apoptosis.

Selenium-containing Thioredoxin Reductase Inhibitor Ethaselen Sensitizes Non-Small Cell Lung Cancer to Radiotherapy

Thioredoxin Reductase Inhibitor Ethaselen Inhibits Cancer Metastasis

The Antimetastatic Effect and Underlying Mechanisms of Thioredoxin Reductase Inhibitor Ethaselen.

Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest

Synergism Between Thioredoxin Reductase Inhibitor Ethaselen and Sodium Selenite in Inhibiting Proliferation and Inducing Death of Human Non-Small Cell Lung Cancer Cells.

[Correlation of plasma thioredoxin reductase activity to growth of H22 hepatocellular carcinoma xenografts in Kunming mice].

Inhibition of Thioredoxin Reductase by a Novel Series of Bis-1,2-benzisoselenazol-3(2h)-ones: Organoselenium Compounds for Cancer Therapy.

Synergistic Inhibition of Sunitinib and Ethaselen Against Human Colorectal Cancer Cells Proliferation.

Cryptotanshinone inhibits proliferation and induces apoptosis via mitochondria-derived reactive oxygen species involving FOXO1 in estrogen receptor-negative breast cancer Bcap37 cells

The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects.

A Novel Organoselenium Compound Induces Cell Cycle Arrest and Apoptosis in Prostate Cancer Cell Lines.

Synthesis, SAR and Biological Evaluation of a Novel Series of 1-(2-chloroethyl)-1-nitroso-3-(2-(3-oxobenzoelenazol-2(3h)-yl)ethyl) Urea: Organoselenium Compounds for Cancer Therapy.

Targeting thioredoxin reductase by eupalinilide B promotes apoptosis of colorectal cancer cells in vitro and in vivo

Unveil the mechanism for EHMT -- A novel triterpenoid inhibits proliferation and induces apoptosis in colon cancer through ROS-mediated JNK signaling pathway

Ethoxy-erianin phosphate inhibits angiogenesis in colorectal cancer by regulating the TMPO-AS1/miR-126-3p/PIK3R2 axis and inactivating the PI3k/AKT signaling pathway